Christina Corsale

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents

Adam D. Cohen, María‐Victoria Mateos, Yaël C. Cohen et al. · Blood · 2022 · 201 citations · Full text

Medicine, Hematology, Oncology +17

The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)

Jens Hillengaß, Adam D. Cohen, Mounzer Agha et al. · Blood · 2023 · 29 citations

Medicine, Hematology, Pharmacology +14

Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1-3 Prior Lines of Therapy: Updated Results from CARTITUDE-2

Yaël C. Cohen, Adam D. Cohen, Michel Delforge et al. · Blood · 2021 · 26 citations

Medicine, Hematology, Oncology +17

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Niels WCJ van de Donk, Mounzer Agha, Adam D. Cohen et al. · Blood · 2022 · 26 citations

Medicine, Hematology, Oncology +17

Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.

Niels W.C.J. van de Donk, Mounzer Agha, Adam D. Cohen et al. · Journal of Clinical Oncology · 2022 · 21 citations

Medicine, Immunology, Oncology +13